Quality statement 2: First-line treatment

Quality statement

People with stable angina are offered a short-acting nitrate and either a beta-blocker or calcium-channel blocker as first-line treatment.

Quality measure

Structure: Evidence of local arrangements to ensure that people with stable angina are offered a short-acting nitrate and either a beta-blocker or calcium-channel blocker as first-line treatment.

Process: Proportion of people newly diagnosed with stable angina who are prescribed a short-acting nitrate and either a beta-blocker or calcium-channel blocker as first-line treatment.

Numerator – the number of people in the denominator prescribed a short-acting nitrate and either a beta-blocker or calcium-channel blocker as first-line treatment.

Denominator – the number of people newly diagnosed with stable angina.

What the quality statement means for each audience

Service providers ensure systems are in place to offer people with stable angina a short-acting nitrate and either a beta-blocker or a calcium-channel blocker as first-line treatment.

Healthcare professionals offer people with stable angina a short-acting nitrate and either a beta-blocker or a calcium-channel blocker as first-line treatment.

Commissioners ensure they commission services that offer people with stable angina a short-acting nitrate and either a beta-blocker or a calcium-channel blocker as first-line treatment.

People with stable angina are offered drug treatment to take for immediate relief from an attack of angina (a short-acting nitrate) and another drug to take every day (either a beta-blocker or a calcium-channel blocker) to prevent episodes of stable angina.

Source guidance

NICE clinical guideline 126 recommendations 1.3.3 and 1.4.7.

Data source

Structure: Local data collection.

Process: Local data collection. Contained within NICE audit support for management of stable angina (NICE clinical guideline 126): criteria 1 and 5a.